SecBot SecBot

LFCR

LIFECORE BIOMEDICAL, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001005286 Biotech & Drug Discovery
$6.42 +0.00 (+0.00%)
Nov 16 4:00 PM ET · prev $6.42
Market cap
$242.6M
Micro cap
Consensus
Hold
0% Buy or better · 10 analysts
Median target
$6.28
−2% · range $6.28–6.28
1 year
−18.7%
from $7.90 · Nov 17
30 days
+0.5%
from $6.39
52-week range
$3.66–8.82
−27% from high · low Mar 27
Avg volume 20D
377.5K
Oct 30 spike 1.02M
Short interest
1.72M
≈4.5% of shares · −4.5%
Days to cover
3.5
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read MIXED 11 reports · 90 days
Balance 2 bearish · 4 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 10/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q3 2026: 9 added (0 new), 11 trimmed or exited.

  • AnalystsMIXED

    0 of 10 rate it Buy or better. Price is above every target.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.182 → −$0.100 over 90 days.

  • Short sellersSTEADY

    Short interest −4.5% to 1.72M shares. 3.5 days to cover, ≈4.5% of shares.

  • TrendRANGE

    10% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
MARSHALL WACE, LLPADD259,144$1.7M
Allspring Global Investments Holdings, LLCADD168,642$1.1M
RENAISSANCE TECHNOLOGIES LLCADD163,000$1.1M
LPL Financial LLCTRIM145,000$954.1K
UBS Group AGTRIM54,942$361.5K
BNP PARIBAS FINANCIAL MARKETSADD39,883$262.4K
Squarepoint Ops LLCTRIM23,275$153.2K
SIMPLEX TRADING, LLCTRIM17,125$112.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Hold 0% rate it Buy or better
Strong Buy0Buy0Hold7Sell1Strong Sell2
12-month targets · 2 analysts

Price is above the highest target. Median implies −2%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 29, 2026Barrington Research
DOWNGRADE
DOWNGRADEMarket Perform
Sep 28, 2026William Blair
DOWNGRADE
DOWNGRADEMarket Perform
Jun 16, 2026Barrington Research
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 4, 2026
HOUDE LOVAS KATRINA
Director
Jun 4, 2026
AWARD25,907 sh
Jun 4, 2026
Korenberg Matthew E
Director
Jun 4, 2026
AWARD25,907 sh
Jun 4, 2026
Johnson Paul Harold
Director
Jun 4, 2026
AWARD25,907 sh
Jun 4, 2026
Aryeh Jason
Director
Jun 4, 2026
AWARD25,907 sh
Jun 4, 2026
Antunes Humberto Calheiros
Director
Jun 4, 2026
AWARD25,907 sh
Jun 4, 2026
Schechter Joshua
Director
Jun 4, 2026
AWARD25,907 sh
Jun 4, 2026
OBUS NELSON
Director
Jun 4, 2026
AWARD25,907 sh
Jun 4, 2026
Kiper Christopher S
Director
Jun 4, 2026
AWARD25,907 sh

Earnings setup

Estimates
−$0.10
EPS estimate, this quarter
+45%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.10-$0.14–-$0.05+0.0%$37.7M
Next Q-$0.28-$0.30–-$0.27+0.0%$27.1M
Current FY-$1.83-$1.83–-$1.83-81.8%$120.4M
Next FY-$0.88-$1.08–-$0.76+0.0%$131.0M

Short side

FINRA· Oct 30, 2026
1,722,308
shares short
-4.5%
vs prior settlement
3.5
days to cover
≈4.5%
of shares outstanding
Trading halts
Sep 28, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

14 filings · 6 press releases · 3 bullish · 4 bearish · 7 neutral
All LFCR filing & press-release reports (20)